Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance ZD1839 (Iressa) in Advanced NSCLC
NCT00090675Phase 3Withdrawn
- Sponsor
- AstraZeneca
- Start
- Jan 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Planned start Jan 2006; status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00090675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090675.